Beranda › Leukemia Mieloid Akut › California › Sacramento
Uji klinis Leukemia Mieloid Akut di Sacramento, CA
12 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Sacramento (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Menerima pesertaFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Mercy Cancer Center - Sacramento, Sacramento
- Woodland Memorial Hospital, Woodland · 16 mi jauhnya
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Menerima pesertaFase 1
- UC Davis, Sacramento
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Menerima pesertaFase 3
- University of California Davis Comprehensive Cancer Center, Sacramento
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Menerima pesertaFase 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Menerima pesertaStudi observasional
- Sutter Medical Center, Sacramento
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Menerima pesertaFase 2
- University of California Davis Health (UC Davis Health), Sacramento
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1/2
- University of California, Davis, Sacramento
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Menerima pesertaFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Uji klinis Leukemia Mieloid Akut di kota lain
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Studi lain di Sacramento
- Kanker Paru Non-Sel Kecil29 studi
- Kanker Paru22 studi
- Kanker Payudara20 studi
- Kanker Prostat19 studi
- Kanker Metastatik16 studi
- Gagal Jantung12 studi
- Kanker Pankreas12 studi
- Kanker (semua jenis)11 studi
- Kanker Kolon11 studi
- Kanker Kandung Kemih10 studi
- Kanker Kolorektal10 studi
- Diabetes Tipe 29 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.